Range Low Price High Price Comment
30 days $62.20 $75.66 Monday, 29th Apr 2024 CYTK stock ended at $62.53. This is 4.30% less than the trading day before Friday, 26th Apr 2024. During the day the stock fluctuated 4.50% from a day low at $62.20 to a day high of $65.00.
90 days $61.33 $84.05
52 weeks $25.98 $110.00

Historical Cytokinetics prices

Date Open High Low Close Volume
Feb 01, 2016 $7.61 $7.72 $7.42 $7.56 347 700
Jan 29, 2016 $7.29 $7.70 $7.22 $7.70 396 500
Jan 28, 2016 $7.85 $7.85 $7.28 $7.30 338 400
Jan 27, 2016 $7.98 $8.10 $7.72 $7.80 260 400
Jan 26, 2016 $8.13 $8.18 $7.71 $8.01 287 900
Jan 25, 2016 $7.94 $8.22 $7.80 $8.11 273 800
Jan 22, 2016 $8.15 $8.28 $7.83 $7.98 300 100
Jan 21, 2016 $8.10 $8.32 $7.79 $8.06 384 500
Jan 20, 2016 $7.97 $8.14 $7.32 $8.08 832 500
Jan 19, 2016 $8.85 $9.00 $7.88 $8.16 536 000
Jan 15, 2016 $8.54 $8.75 $8.26 $8.72 395 300
Jan 14, 2016 $8.92 $9.00 $8.29 $8.79 515 800
Jan 13, 2016 $9.65 $9.74 $8.73 $8.82 555 800
Jan 12, 2016 $8.99 $9.66 $8.99 $9.63 710 800
Jan 11, 2016 $9.57 $9.57 $8.71 $8.96 480 100
Jan 08, 2016 $9.85 $10.06 $9.41 $9.47 347 100
Jan 07, 2016 $9.77 $10.10 $9.55 $9.82 440 800
Jan 06, 2016 $10.44 $10.44 $9.86 $9.94 375 200
Jan 05, 2016 $10.09 $10.71 $9.95 $10.60 540 300
Click to get the best stock tips daily for free!

About Cytokinetics

Cytokinetics Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in pati... CYTK Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT